Xylem Appoints Mark Morelli to Board of Directors
RYE BROOK, N.Y.–(BUSINESS WIRE)–Jan. 31, 2022– Global water technology leader, Xylem (NYSE:XYL), today announced the appointment of Mark Morelli to the Company’s Board of Directors, effective February 3, 2022. Mr. Morelli currently serves as President and CEO of Vontier Corporation, the $3B global industrial technology company focused on smarter mobility. He brings nearly two decades... Read more
FDA approves Roche’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient need Basel, 31 January 2022 – Roche (SIX: RO, ROG; OTCQX:... Read more
Thermo Fisher Scientific Earns Top Score for LGBTQ+ Workplace Equality for Seventh Consecutive Year
Thermo Fisher Scientific Earns Top Score for LGBTQ+ Workplace Equality for Seventh Consecutive Year WALTHAM, Mass., Jan. 27, 2022 /PRNewswire/ — Thermo Fisher Scientific Inc., (NYSE:TMO), the world leader in serving science, received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI) for the seventh consecutive year. As the... Read more
Xylem Earns Top Score for Workplace Equality from Human Rights Campaign for Third Year Running
RYE BROOK, N.Y.–(BUSINESS WIRE)–Jan. 27, 2022– Xylem (NYSE:XYL), a leading global water technology company, has today announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index. This is the third year in a row that Xylem has earned top marks on the U.S. benchmarking survey which measures... Read more
Danaher Reports Fourth Quarter And Full Year 2021 Results
WASHINGTON, Jan. 27, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the fourth quarter and full year 2021. All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended December 31, 2021, net earnings were $1.8 billion, or $2.39 per diluted common share which represents a... Read more
Advancing Imaging Frontiers with the new Oxford-ZEISS Centre of Excellence
In December 2021, ZEISS entered a strategic partnership with the Kennedy Institute of Rheumatology (KIR) and the Institute of Developmental and Regenerative Medicine (IDRM), developing the Oxford-ZEISS Centre of Excellence (Oxford-ZCoE). The Kennedy Institute of Rheumatology (KIR) is a world-leading medical research centre where discovery research drives development of transformative therapies for chronic inflammatory and... Read more